Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00692354 | Safety Study to Evaluate CHR-2797 in Patients With Advanced Tumours | PHASE1 | COMPLETED | 41 | — | — | Oct 1, 2004 | Mar 1, 2008 | Aug 6, 2010 | - | — |
| Name | Type | Description |
|---|---|---|
| CHR-2797 (tosedostat) | DRUG | Drug was given orally, once daily, ensuring a dosing interval of approximately 24 hours. Dose escalations took place starting at 10mg and escalating (per protocol) as follows: 20, 40, 90, 130, 180, 240 and 320 mg |
Inclusion Criteria: * Signed, informed consent * Histological or cytologically confirmed malignant solid tumour refractory to standard therapy or for which no standard therapy exists * Evaluable disease * Recovered from the acute adverse effects of prior therapies (excluding alopecia and grade 1 ne...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab, V503, GARDASIL |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| AstraZeneca PLC | AZN | 1 | — | Trastuzumab deruxtecan |